RVMD Stock — Revolution Medicines, Inc.: Metrics

Market overview

2 metrics

Share price

$209.23

Market cap

$44.98B

Price action

19 metrics

Price change (1W)

-0.7%

Price change (30D)

+15.0%

Price change (3M)

+38.7%

Price change (6M)

+108.8%

Price change (YTD)

+163.5%

Price change (1Y)

+452.7%

Trailing year

Price change (5Y)

+611.9%

52-week high

$221.15

52-week low

$38.95

Change from 52-week high

-5.1%

Change from 52-week low

+438.8%

Annualized volatility

67.8%

Beta

1.2

RSI (14D)

56.0

Price vs SMA 50

+7.9%

Price vs SMA 200

+59.1%

Avg volume (3M)

2.39M

Relative volume

0.8

Average dollar volume

$436.79M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

214.34M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

17.3

reciprocal yield 5.8%

FCF yield

-2.7%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-3.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-05

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$1.63B

Net income (TTM)

−$1.77B

Trailing 12 months

Diluted EPS (TTM)

$-8.86

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-46.35

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$0

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+11.8%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-67.8%

Return on assets

-40.9%

Debt / equity

—

Current ratio

11.4

EBITDA (TTM)

−$1.62B

Free cash flow (TTM)

−$1.23B

Quick ratio

11.4

Interest coverage

-27.4

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$3.94B

Latest balance sheet

Cash & equivalents

$815.43M

Total assets

$4.32B

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$1.22B

Capital expenditures (TTM)

$9.10M

R&D (TTM)

$1.30B

SG&A (TTM)

—

Stock compensation (TTM)

$218.77M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

699

13F filer change QoQ

+174

Institutional ownership

106.9%

Short interest

3 metrics

Short interest

4.5%

Latest settlement · 6.4 days to cover

Days to cover

6.4d

Short-squeeze score

63 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$53.90M

Insider-sentiment score

47 / 100

Risk flags

1 metrics

Going concern

—

RVMD · Revolution Medicines, Inc.

RVMD metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search